Cascadia Acquisition Corp.: Nasdaq/NYSE listing notice — Cascadia Acquisition Corp. receives Nasdaq MVLS deficiency notice; 180-day cure period to Oct 30, 2023

Cascadia Acquisition Corp.

Nasdaq notified company on May 3, 2023 that Minimum Value of Listed Securities (MVLS) was below $50 million for 30 consecutive trading days.
Company has 180 calendar days, until October 30, 2023, to regain compliance by closing MVLS at or above $50M for ten consecutive business days.
If unable to regain Global Market compliance, company may transfer listing to Nasdaq Capital Market if conditions are met.
No immediate effect on listing or trading; company intends to monitor and evaluate options to resolve deficiency.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Cascadia Acquisition Corp. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5450(b)(2)(A)

Exact text from the filing

May 3, 2023, Cascadia Acquisition Corp., a Delaware corporation (the “ Company ”), received a letter (the “ Letter ”) from the staff at The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, for the 30 consecutive trading days prior to the date of the Letter, the Company’s Minimum Value of Listed Securities (“ MVLS ”) was below the minimum of $50 million required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A). The Letter is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or tra

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-23-139399

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.